Gupta Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Gupta Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-357	Closed	-$23K	–	1276
2015 Q4	$23K	Buy	+357	New	+$22.1K	0.01%	628
2015 Q3	–	Sell	-35,850	Closed	-$2.12M	–	1345
2015 Q2	$2.12M	Sell	35,850 -3,313	-8%	-$204K	0.52%	50
2015 Q1	$2.44M	Buy	+39,163	New	+$2.28M	0.72%	37

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Gupta Wealth Management's TEVA Position: Q1 2016 in Review

Gupta Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 357 shares — an estimated $23K sold.

Gupta Wealth Management first reported a position in TEVA in Q1 2015 and held it in 3 quarters. The position peaked at $2.44M in Q1 2015. 837 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Gupta Wealth Management reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Gupta Wealth Management sold 357 Teva Pharmaceuticals shares in Q1 2016, an estimated $23K.
Gupta Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 3 quarters.
Gupta Wealth Management's Teva Pharmaceuticals position peaked at $2.44M in Q1 2015.
837 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Gupta Wealth Management's 13F filing for Q1 2016, filed 16 May 2016.